Vertex Pharmaceuticals Reports Director Election and Officer Departure

Vertex Pharmaceuticals Inc. reported the election of a new director and the departure of a principal officer in a Form 8-K filed with the SEC on May 13, 2026.

The filing covers two items required under SEC rules: Item 5.02 on departure of directors or principal officers and Item 5.07 on submission of matters to a vote of security holders. Vertex, with CIK 0000875320 and ticker VRTX, submitted the document under accession number 0000875320-26-000204.

The officer change removes one individual from a principal role while the director election adds a new member to the board. The filing specifies the named individual, the effective date of each action and any cited cause, per standard Item 5.02 disclosure requirements.

Prior to the filing the board and officer roster reflected the departed officer in the principal position; the new state reflects the officer's exit and the addition of the elected director. Both changes took effect on or before the May 13, 2026 filing date.

The departures and elections require Vertex to update its internal governance records and may necessitate follow-on disclosures such as revised officer certifications or proxy statement updates for the next annual meeting. The board composition shift alters who must approve certain corporate actions under Vertex bylaws and Delaware corporate law.

Standard SEC rules require the company to file any material contract amendments or compensatory arrangements tied to the officer departure within four business days if not previously disclosed.

This marks the latest board-level change Vertex has reported via Form 8-K. Public companies file Item 5.02 disclosures to notify investors and regulators of leadership transitions that can affect executive compensation, succession planning and board oversight responsibilities.

The election of directors under Item 5.07 typically follows a shareholder vote whose results must be reported within four business days.

The 8-K itself constitutes the primary public record of the events. No additional immediate regulatory deadlines for other agencies arise from the filing, though the updated board roster will appear in Vertex's next proxy statement and annual report.